PeptideStack
5.2kquestions
20kanswers
220users

Is 98.8% a realistic purity ceiling for liraglutide given its chain length?

Asked 31 Jul 2025Modified 9 months agoViewed 3.1k times
4

Conditions: 98.8% · liraglutide.

Please show the division. I want to check my own against yours.

I would like the general form as well as the specific number, so I can apply it again.

Where is my error, and what is the correct working?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
peptide-mapping
peptide-mapping

Enzymatic digestion followed by LC-MS/MS to confirm sequence rather than just mass. The method that catches a scrambled sequence or a D-amino-acid…

83 questions
shareeditfollowflag
RP
askedretest_please13k2831 Jul 2025

2 Answers

Accepted answer first, then by votes
6

Accepted answer

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

Mechanically, buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 5 Nov 2025 by Dr_Bram_Verhoeven — added a caveat about sampling

shareimprove this answerflag
DV
answered · acceptedDr_Bram_Verhoeven85k24814 Oct 2025
7This is the first explanation of that which has actually made sense to me. – tobias_maartens 8 months ago
8Note that the label instructions differ between agents on precisely this point. – liam_bracken 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
51

Purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

In practice, gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 5 Nov 2025 by jana_horakova — corrected a unit error in the worked example

shareimprove this answerflag
JH
answeredjana_horakova15k2725 Oct 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.